Skip to content

Mechanism of action of the quadratus lumborum block

Mechanism of action of the quadratus lumborum block

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2017-004221-32-BE
Enrollment
60
Registered
2018-06-21
Start date
2018-08-06
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing abdominal laparoscopy or laparotomy

Interventions

Trade Name: Naropin 0,75% (R): Ropivacaine 0,75%: (Astra-Zeneca) Iomeron 300: 61,24% w/v of iomeprol equivalent to 30% iodine or 300mg iodine/ml (Bracco UK Limited) Pharmaceutical Form:

Sponsors

Department of Anesthesia Reanimation of University of Liege
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults patients undergoing abdominal surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: Allergy to local anesthetics, or contrast media coagulation disorder and renal dysfunction

Design outcomes

Primary

MeasureTime frame
Main Objective: To determine the mechanism of action of the quadrates lumborum block for pain relief after abdominal surgery;Secondary Objective: To examine different approaches for the quadrates lumborum block and determine the best one;Primary end point(s): Determine the mechanism of action of the different approaches;Timepoint(s) of evaluation of this end point: Two hours after completion of the surgery

Secondary

MeasureTime frame
Secondary end point(s): No secondary end points;Timepoint(s) of evaluation of this end point: 3 Hours postoperatively

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026